دورية أكاديمية
Quality of erections by age group in men with erectile dysfunction.
| العنوان: | Quality of erections by age group in men with erectile dysfunction. |
|---|---|
| المؤلفون: | Kaminetsky JC; University Urology Associates, New York, NY, USA., Stecher V; Pfizer Inc., New York, NY, USA., Tseng LJ; Pfizer Inc., New York, NY, USA. |
| المصدر: | International journal of clinical practice [Int J Clin Pract] 2017 Oct; Vol. 71 (10). Date of Electronic Publication: 2017 Sep 11. |
| نوع المنشور: | Journal Article; Meta-Analysis |
| اللغة: | English |
| بيانات الدورية: | Publisher: Hindawi Country of Publication: India NLM ID: 9712381 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1742-1241 (Electronic) Linking ISSN: 13685031 NLM ISO Abbreviation: Int J Clin Pract Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2022- : Mumbai : Hindawi Original Publication: Esher [England] ; Bronxville, N.Y. : Medicom International, c1997- |
| مواضيع طبية MeSH: | Penile Erection*, Erectile Dysfunction/*drug therapy , Phosphodiesterase Inhibitors/*therapeutic use , Sildenafil Citrate/*therapeutic use, Adult ; Double-Blind Method ; Humans ; Male ; Middle Aged ; Patient Satisfaction ; Randomized Controlled Trials as Topic ; Surveys and Questionnaires |
| مستخلص: | Aims: The aim of this study was to assess erection quality with sildenafil vs placebo and adverse events (AEs) according to age (≤45, 46-55 and ≥56 years) in 997 men with erectile dysfunction (ED) using pooled data from four randomized, double-blind, placebo-controlled, flexible-dose trials. Methods: The trials included 6- to 10-week treatment periods. The starting sildenafil dose was 50 mg, taken ~1 hour before sexual activity but not more than once daily, with subsequent adjustment to 100 or 25 mg based on efficacy and safety. Exclusion criteria included blood pressure <90/50 or >170/110 mmHg, taking nitrate therapy or nitric oxide donors, severe cardiac failure/unstable angina or recent stroke or myocardial infarction. Changes from baseline in Quality of Erection Questionnaire (QEQ), International Index of Erectile Function (IIEF) and Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) scores were analysed. Results: Improvements in QEQ scores with sildenafil vs placebo were significant (P<.0001) for the overall sample (33.7 sildenafil; 8.1 placebo) and each age group (≤45 years: 38.5 sildenafil, 13.9 placebo; 46-55 years: 34.9 sildenafil, 5.8 placebo; ≥56 years: 26.9 sildenafil, 4.9 placebo). IIEF Erectile Function domain (P<.0001), question 3 (achieving erection; P<.003), and question 4 (maintaining erection; P<.001) scores also improved significantly for the overall sample and each age group. Treatment satisfaction was significantly greater (P<.0001) with sildenafil vs placebo for the overall sample and each age group. The most common AEs with sildenafil were headache, flushing and nasal congestion in all age groups. Conclusions: Sildenafil significantly improved erection quality across all age groups of men with ED. Efficacy improvements with sildenafil were consistent with the QEQ, IIEF, and EDITS. AEs were comparable across age groups. ClinicalTrials.gov ID: NCT00159900, NCT00147628, NCT00301262, NCT00343200. (© 2017 John Wiley & Sons Ltd.) |
| التعليقات: | Comment in: J Urol. 2018 Feb;199(2):328. (PMID: 29357537) |
| سلسلة جزيئية: | ClinicalTrials.gov NCT00159900; NCT00147628; NCT00301262; NCT00343200 |
| المشرفين على المادة: | 0 (Phosphodiesterase Inhibitors) BW9B0ZE037 (Sildenafil Citrate) |
| تواريخ الأحداث: | Date Created: 20170912 Date Completed: 20180712 Latest Revision: 20181202 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1111/ijcp.12976 |
| PMID: | 28892218 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1742-1241 |
|---|---|
| DOI: | 10.1111/ijcp.12976 |